Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
While Esperion announced a statistically-significant outcome for heart med Nexletol (bempedoic acid) over the weekend, markets were less than impressed with the size of the treatment benefit. 6 March 2023
South Korea’s Celltrion Healthcare saw its shares gain more than 7% to 57,700 Korean won on Friday, after it presented new data for its novel subcutaneous infliximab treatment, CT-P13 SC, also known as Remsima, at the European Crohn’s and Colitis Organization congress last week. 6 March 2023
USA-based clinical stage biotech Mineralys Therapeutics (Nasdaq: MLYS) announced positive data from the Target-HTN Phase II study that demonstrated clinically-meaningful blood pressure reduction with once-daily dosing of lorundrostat. 6 March 2023
Shares of Boston, USA-based biotech Praxis Precision Medicines sank almost 66% to $1.00 on Friday, after it said it would move its most advanced experimental drug into late-stage human testing, despite reporting that ulixacaltamide failed to meet the main goal of a mid-stage clinical trial. 4 March 2023
A merger between Flamingo Therapeutics and Dynacure will create a new oncology company, retaining the Flamingo name, advancing lead candidates danvatirsen and FTX-001. 3 March 2023
Swedish rare disease specialist Hansa Biopharma today announced today that Matthew Shaulis will join the company effective March 16 as chief commercial officer and president of its US affiliate 3 March 2023
G-protein coupled receptor (GPCR) company Confo Therapeutics has announced a worldwide licensing agreement with US pharma major Eli Lilly for the Belgian firm’s clinical stage CFTX-1554 and back-up compounds. 2 March 2023
USA-based Ambrx Biopharma and partner NovoCodex Biopharmaceuticals have announced an update on ACE-Breast-02, a Phase III breast cancer trial. 2 March 2023
Dutch autoimmune diseases specialist argenx said today that Karen Massey will join the company as chief operating officer COO, effective March 13, 2023. 2 March 2023
Florida, USA-based Avenue Therapeutics, which was founded by Fortress Biotech, today announced that it has entered into an exclusive license agreement with AnnJi Pharmaceutical, a Taiwanese clinical-stage drug company. 2 March 2023
Shares of US biotech Cidara Therapeutics rose almost 20% to $1.81 in early trading as the company announced promising efficacy and safety data from a planned interim analysis of the ongoing Phase IIa trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain, as of a February 13, 2023 data cut-off. 1 March 2023
Shanghai Junshi Biosciences had more positive news, this time on its monoclonal antibody (MAb) candidate ongericimab, adding to the successful trials results for its toripalimab in breast cancer last week. 1 March 2023
In a second financing within one year, China-based Oricell Therapeutics has announced the close of a $45 million Series B1 investment round. This adds to the $125 million Series B fund that was raised in July 2022. 1 March 2023
US precision medicines company Frontier Medicines today announced the addition of Christo Shalish to the leadership team as senior vice president (SVP) and head of business development. 28 February 2023
Sino-American biotech BeiGene yesterday reported financial results, showing that revenues for the fourth quarter and full year 2022 was $380.1 million, missing consensus estimates of $345 million by 2%, and $1.4 billion, respectively, compared to $214.0 million and $1.2 billion in the prior-year periods. 28 February 2023
New York-based central nervous system (CNS) specialist Axsome Therapeutics has hit a regulatory snag in the development of AXS-05 (dextromethorphan/bupropion). 28 February 2023
US CNS specialist Aptinyx saw its shares plunge more than 56% to $0.26, after it released Phase II clinical study results evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies. 28 February 2023
The Dutch business of Rhythm Pharmaceuticals has acquired Xinvento, a Netherlands-based biotech focused on therapies for congenital hyperinsulinism (CHI). 27 February 2023